With the exception of age (clinical trial patients are approximately 9 years younger), the baseline characteristics of the patients eligible for this analysis were similar to those observed in randomized, clinical trials of EGFR Mut+ NSCLC [7,13,16]. Here, EGFR is linked to non-small cell lung carcinoma.